Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 19c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.78), $0.19 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $68.7 million versus the consensus estimate of $63.13 million.

For the full year of 2026, the Company expects total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Morgan Stanley Upgrades Mitsubishi Chemical Holdings (4188:JP) (MTLHY) to Overweight
• GE Vernova T&D India (GVTD:IN) PT Raised to INR5,300 at Emkay Global